India's largest biotech company, Biocon’s subsidiary - Clinigene International has entered into a collaborative clinical research agreement with Pacific Biomarkers Inc. (PBI), a Seattle, WA-based limited liability company. The agreement is to address the specialty biomarker and high end clinical trial laboratory needs of the global pharmaceutical and biotechnology industry.
Clinigene, is an India-based clinical research organization (CRO) that offers end-to-end clinical and laboratory services for accelerating clinical research, and Pacific Biomarkers Inc. (FBI), is a Seattle, WA-based company that provides premier biomarker and specialty efficacy testing services to the drug development industry.
Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies. The drug major also produces mycophenolate mofetil, sirolimus and tacrolimus.
